Inovio Pharmaceuticals, Inc.
INO Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$0.90
KIRA · Stoqly’s AI analyst, in plain words
- Inovio Pharmaceuticals, Inc. had $0.1M of revenue in fiscal 2025, down 70.0% on the year before. Over five years, revenue changed −61.2% a year on average.
- Its operating margin was −132,958.8%, down 81,352.3 pts: of every 100 in sales, about −132,959 is left after running the business.
- Inovio Pharmaceuticals, Inc. lost $84.9M in fiscal 2025.
- Free cash flow was −$88.9M in fiscal 2025, −136,164.0% of revenue.
Market cap
$73.2M
P/E
—
Revenue
$0.1M
Net income
−$84.9M
Free cash flow
−$88.9M
Operating margin
−132,958.8%
Inovio Pharmaceuticals, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−70.0%
No. Sales fell 70.0% last year.
Does it make a profit?
−130,085.6%
No. It lost money last year.
Does profit turn into cash?
−136,164.0%
No. It spent more cash than it brought in.
How healthy are the accounts?
0 / 7
Weak. It passes 0 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Inovio Pharmaceuticals, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 12, 2026
- Legal name
- INOVIO PHARMACEUTICALS, INC.
- CIK
- 0001055726
Inovio Pharmaceuticals, Inc. · INO
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $1.8M | $10.3M | $0.8M | $0.2M | $0.1M |
| Revenue growth | −76.1% | 478.2% | −91.9% | −73.8% | −70.0% |
| Operating margin | −16,971.9% | −2,607.3% | −17,300.5% | −51,606.5% | −132,958.8% |
| Net income | −$304M | −$280M | −$135M | −$107M | −$84.9M |
| Net margin | −17,109.5% | −2,726.7% | −16,240.1% | −49,244.3% | −130,085.6% |
| Diluted EPS | −$17.45 | −$14.07 | −$6.09 | −$3.95 | −$1.81 |
| Cash | |||||
| Cash from operations | −$216M | −$216M | −$124M | −$104M | −$88.6M |
| Capital expenditure | $1.2M | $1.0M | $0.3M | $0.5M | $0.3M |
| Free cash flow | −$217M | −$217M | −$125M | −$105M | −$88.9M |
| FCF margin | −12,223.3% | −2,116.3% | −14,986.4% | −48,009.4% | −136,164.0% |
| Share count change | −88.8% | 14.3% | 11.5% | 22.5% | 72.6% |
| Debt and strength | |||||
| Cash and short-term investments | $401M | $253M | $145M | $94.1M | $58.5M |
| Shareholders' equity | $400M | $222M | $117M | $68.5M | $24.1M |
| Current ratio | 6.8x | 3.3x | 3.6x | 2.8x | 1.4x |
| Interest coverage | −155.6x | −213.4x | −117.7x | −632.2x | — |
| Returns and quality | |||||
| Return on equity | −70.6% | −90.0% | −79.5% | −115.4% | −183.5% |
| Return on tangible equity | −78.6% | −133.4% | −115.1% | −156.6% | −352.5% |
| Piotroski F-score | 2 | 2 | 3 | 1 | 0 |
| Altman Z'' | −2.6 | −13.1 | −30.1 | −51.3 | −85.4 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Inovio Pharmaceuticals, Inc. · INO
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.90 a share, the company is worth $73.2M.
Source: SEC EDGAR XBRL filings (CIK 0001055726). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.